Eating Disorders & GLP-1 RAs

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes. LP-1 RAs are now being used as an approved or off-label treatment for weight loss.

here is limited research available to help researchers, clinicians, and patients/consumers to understand the relationships between GLP-1 RAs and eating disorders (9). However, it is thought that GLP-1 RAs may negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information for clinicians, researchers, and patients/consumers to understand more about the link between GLP-1 RAs and eating disorders, including risks, physical impacts, psychological impacts, and practice recommendations.


« Back to Browse Resources

See also

Eating Disorders - Protecting your oral health

Read more

Eating Disorders Information and Support for Australians – Resource Review 

In recognition that body image and Eating Disorders are a pressing issue within the Australian community, the Commonwealth of Australia commissioned this report to be prepared by the Butterfly Foundation (“Butterfly”) on behalf of the National Eating Disorders Collaboration (NEDC).

Read more

Mind, Body & Fertility: The Connection Between Fertility Care, Disordered Eating and Eating Disorders

People seeking fertility care are significantly more likely than the general population to have an experience of body image issues, disordered eating or an eating disorder.

Read more

Issue 55 | Theory and Practice: Screening and Assessment Tools for Eating Disorders

Theory and Practice: Screening and Assessment Tools for Eating DisordersEditor's Note: Welcome to this edition of the NEDC e-Bulletin, where we delve into the NEDC’s recent and upcoming collaborations with local PHNs and then examine different practical screening and assessment tools to help you detect the possible presence of an eating disorder.

Read more